Answers are grounded in this paper and cite their sources.
Key Points In the phase 3 TOWER study, exposure-adjusted AE rates were lower for blinatumomab vs SOC chemotherapy in Ph− B-cell r/r ALL patients. These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for B-cell r/r ALL patients.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: